Material Insights · Understanding the Material World

GLP-1 receptor agonists: Overview

What it does

The job the technology does for people, in a short paragraph

GLP-1 receptor agonists are medicines that copy a gut hormone released after meals. They help the body control blood sugar and make people feel full sooner. The first, exenatide, was approved in the United States in 2005 [2]. They are used for type 2 diabetes and obesity, conditions that affect 830 million and more than a billion people [3, 4].

as of 2026-11-11

How it works

The working principle in plain words, step by step

After a meal, cells in the gut release a short protein hormone, GLP-1. It docks on a receptor, a protein on the surface of other cells, like a key in a lock. In the pancreas this tells beta cells to release more insulin when blood sugar is high [1]. It also slows the emptying of the stomach and acts on the brain to reduce appetite [1]. The natural hormone is broken down within minutes, so it cannot work as a medicine [1]. The drugs are peptides changed so that they fit the same receptor but last far longer: exendin-4 from lizard venom, then human GLP-1 with small changes that let it bind to blood proteins and resist breakdown. Semaglutide lasts about 165 hours in the body [1].

as of 2026-11-11

Key figures

The handful of numbers that size it up, each with its unit, year and source

FigureValueUnitYearSource
People living with obesity, more than1billion people– [3]
People living with diabetes830million people2022[4]
Half-life of semaglutide in the body165hours– [1]
Novo Nordisk's reported sales of Wegovy79.1billion DKK2025[5]
Novo Nordisk's own figure for its share of the world GLP-1 diabetes market by value (IQVIA data, 12 months to November 2025)45.8%2025[5]

as of 2026-11-11. The obesity figure is from WHO's guideline of December 2025, which gives no year for it [3]; the sales and market share are Novo Nordisk's own figures from its 2025 financial report, the share based on IQVIA data for November 2025 and covering GLP-1 diabetes medicines only [5].

Where it is used

The main places and products the technology is found in

  • Type 2 diabetes, to help control blood sugar [1]
  • Long-term treatment of obesity in adults [3]
  • Lowering the risk of heart attack and stroke in some people with heart disease and excess weight [1]
  • Primary care clinics, diabetes and obesity services, and pharmacies

as of 2026-11-11

Scale today

How much of it there is now: units in use, made each year and who uses it

Users
Novo Nordisk reports that its diabetes and obesity medicines reached 45.6 million patients in 2025 [5]
Unit
people
Year
2025
Note
The company's own estimate, a 12-month total covering all its diabetes and obesity products, including insulin, so it is only a guide; no world count of GLP-1 users was found.

as of 2026-11-11

Sources

  1. GLP-1-based therapy for obesity Lasker Foundation (2024 Lasker~DeBakey Clinical Medical Research Award), 2024
  2. Dr. John Eng to Receive Golden Goose Award The Science Coalition, 2013
  3. WHO issues global guideline on the use of GLP-1 medicines in treating obesity World Health Organization, 2025
  4. Diabetes (fact sheet) World Health Organization, 2026
  5. Financial report for the period 1 January 2025 to 31 December 2025 (company announcement No 4/2026, Form 6-K) Novo Nordisk A/S, filed with the US Securities and Exchange Commission, 2026